Learn More
BACKGROUND Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined. METHODS We conducted searches of the published literature, the Web site of the Food and Drug Administration, and a clinical-trials registry maintained by the drug manufacturer(More)
CONTEXT Statins reduce low-density lipoprotein cholesterol (LDL-C) levels and slow progression of coronary atherosclerosis. However, no data exist describing the relationship between statin-induced changes in high-density lipoprotein cholesterol (HDL-C) and disease progression. OBJECTIVE To investigate the relationship between changes in LDL-C and HDL-C(More)
BACKGROUND Unfractionated heparin (UFH) is the most widely used antithrombin during percutaneous coronary intervention (PCI). Despite significant pharmacological and mechanical advancements in PCI, uncertainty remains about the optimal activated clotting time (ACT) for prevention of ischemic or hemorrhagic complications. METHODS AND RESULTS We analyzed(More)
OBJECTIVEdTo evaluate the effects of two bariatric procedures versus intensive medical therapy (IMT) on b-cell function and body composition. RESEARCH DESIGN AND METHODSdThis was a prospective, randomized, controlled trial of 60 subjects with uncontrolled type 2 diabetes (HbA 1c 9.7 6 1%) and moderate obesity (BMI 36 6 2 kg/m 2) randomized to IMT alone, IMT(More)
Glycemic control improves immediately after gastric bypass in patients with type 2 diabetes mellitus (T2DM) (1). The Amer-ican Diabetes Association defines complete remission of diabetes as a return to normal glucose levels (HbA 1c , 6%, fasting glucose ,5.6 mmol/L) without glucose-lowering medication for at least 1 year after bariatric surgery (2). Prior(More)
BACKGROUND Lipid-lowering agents are known to reduce long-term mortality in patients with stable coronary disease or significant risk factors. However, the effect of lipid-lowering therapy on short-term mortality immediately after an acute coronary syndrome has not been determined. We did an observational study using data from two randomised trials to(More)
OBJECTIVES We sought to determine whether abciximab therapy at the time of percutaneous coronary intervention (PCI) would favorably affect one-year mortality in patients with diabetes. BACKGROUND Diabetics are known to have increased late mortality following PCI. METHODS Data from three placebo-controlled trials of PCI, EPIC, EPILOG, and EPISTENT, were(More)
OBJECTIVE To evaluate the effects of two bariatric procedures versus intensive medical therapy (IMT) on β-cell function and body composition. RESEARCH DESIGN AND METHODS This was a prospective, randomized, controlled trial of 60 subjects with uncontrolled type 2 diabetes (HbA1c 9.7 ± 1%) and moderate obesity (BMI 36 ± 2 kg/m(2)) randomized to IMT alone,(More)
BACKGROUND Coronary plaque progression and instability are associated with expansive remodeling of the arterial wall. However, the remodeling response during plaque-stabilizing therapy and its relationship to markers of lipid metabolism and inflammation are incompletely understood. METHODS AND RESULTS Serial intravascular ultrasound (IVUS) data from the(More)
BACKGROUND Unfractionated heparin has been the primary anticoagulant therapy for percutaneous coronary intervention for >20 years. Despite the availability of rapid "point of care" testing, little clinical data defining the optimal level of anticoagulation are available. Furthermore, recent reports have advocated the use of low-dose heparin regimens in the(More)